Elevated free fosphenytoin concentrations in uremic sera: Uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin

Therapeutic Drug Monitoring

Volumn 20, Issue 6, 1998, Pages 658-662

  Dasgupta, Amitava ^a   Havlik, Dean ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Fosphenytoin; Protein binding; Uremia

Indexed keywords

CYREBYX; FOSPHENYTOIN SODIUM; HIPPURIC ACID; INDICAN; PHENYTOIN; PRODRUG; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HYPOALBUMINEMIA; PRIORITY JOURNAL; UREMIA;

ANTICONVULSANTS; DRUG INTERACTIONS; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIPPURATES; HUMANS; INDICAN; PHENYTOIN; PROTEIN BINDING; SERUM ALBUMIN; UREMIA;

EID: 0031755844     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199812000-00013     Document Type: Article

References (16)

1. Varia SA, Stella VJ. Phenytoin prodrug. V: in vivo evaluation of some water soluble phenytoin prodrug in dogs. J Pharm Sci 1984; 73:1080-6.
2. Boucher BA. Fosphenytoin, a novel phenytoin prodrug. Pharmacotherapy 1996;16:777-91.
3. Wilensky AJ, Lowden JA. Inadequate serum levels after intrmusclular administration of diphenylhydantoin. Neurology 1973;23: 318-24.
4. Serrano EE, Wilder BJ. Intramuscular administration of diphylhydantoin. Arch Neurol 1974;16:507-13.
5. Hussey EK, Dukes GE, Messenheimer JA, et al. Protein binding of phenytoin and a phenytoin prodrug. Pharm Res 1988:S214. Abstract.
6. Jamerson BD, Donn KD, Powell JR, et al. Absolute bioavailibility of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia 1990;31:592-7.
7. Lai CM, Moore P, Quon CY. Binding of fosphenytoin, phosphate ester pro drug of phenytoin to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenybutazone, valproic acid or warfarin. Res Comm Mol Pathol 1995; 88:51-62.
8. Olson GD, Bennet WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 1975;17:677-84.
9. Shoeman DW, Azarnoff DL. The alteration of plasma proteins in uremia as reflected in their ability to bind digoxin and diphenyl-hydrantoin. Pharmacology 1972;7:169-77.
10. Dodson WE, Loney LC. Hemodialysis reduces the unbound phenytoin in plasma. J Pediatr 1982;101:465-8.
11. Vanholder R, Landschoot NV, DeSmet R, Schoots AD, Ringoir S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988;33:996-1004.
12. Miller JJ, Valdes R. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassay 1992;15:97-107.
13. Stapp Z, Linder MW, Miller JJ, Valdes R. Conversion of fosphenytoin to phenytoin in vitro. Clin Chem 1997;43:5219-20. Abstract.
14. Vaqnholder R, DeSmet R, Ringoir SM. Assesment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992;38:1429-36.
15. Li M, Chung ST, Hong SK, Goldinger JM. Effect of methylguanidine on sodium and organic ion transport. Nephron 1992;60: 349-54.
16. Dasgupta A, Malik M. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein bindings:absence of midmolecular toxins. Am J Nephrol 1994;14:162-8.